IOVA Stock Down -35% after 6-Day Loss Streak
Iovance Biotherapeutics (IOVA) stock hit day 6 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -35% return. The company has lost about $304 Mil in value over the last 6 days, with its current market capitalization at about $862 Mil. The stock remains 65.3% below its value at the end of 2024. This compares with year-to-date returns of 7.8% for the S&P 500.
IOVA develops and commercializes cancer immunotherapies, with six ongoing phase 2 trials including lifileucel for metastatic melanoma, headquartered in San Carlos, California. Is this drop a warning sign or a setup for rebound? Deep dive with Buy or Sell IOVA.
Comparing IOVA Stock Returns With The S&P 500
The following table summarizes the return for IOVA stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | IOVA | S&P 500 |
|---|---|---|
| 1D | -3.7% | -0.4% |
| 6D (Current Streak) | -35.3% | -0.3% |
| 1M (21D) | 47.7% | 2.3% |
| 3M (63D) | -28.4% | 13.8% |
| YTD 2025 | -65.3% | 7.8% |
| 2024 | -9.0% | 23.3% |
| 2023 | 27.2% | 24.2% |
| 2022 | -66.5% | -19.4% |
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact. Take a look at what history tells you about whether past dips like this have been buying opportunities or traps: IOVA Dip Buyer Analysis.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 35 S&P constituents with 3 days or more of consecutive gains and 127 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 23 | 40 |
| 4D | 6 | 60 |
| 5D | 1 | 10 |
| 6D | 1 | 15 |
| 7D or more | 4 | 2 |
| Total >=3 D | 35 | 127 |
Key Financials for Iovance Biotherapeutics (IOVA)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $1.2 Mil | $164.1 Mil |
| Operating Income | $-460.6 Mil | $-395.3 Mil |
| Net Income | $-444.0 Mil | $-372.2 Mil |
Last 2 Fiscal Quarters:
| Metric | 2024 FQ4 | 2025 FQ1 |
|---|---|---|
| Revenues | $73.7 Mil | $49.3 Mil |
| Operating Income | $-86.6 Mil | $-121.2 Mil |
| Net Income | $-78.6 Mil | $-116.2 Mil |
The losing streak IOVA stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.